[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569149":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":12,"responsibleParty":95,"collaborators":7,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":7,"enrollmentInfo":107,"targetDuration":7,"studyType":110,"phases":7,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":122,"whyStopped":7,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Pierre Fabre Medicament","INDUSTRY",null,[9],{"name":10,"affiliation":7,"role":11},"Vincent SIBAUD","PRINCIPAL_INVESTIGATOR",[13,24,33,43,51,61,69,77,87],{"facility":14,"status":7,"city":15,"state":7,"zip":7,"country":16,"countryCode":17,"cosmosGeoPoint":18,"geoPoint":23,"contacts":7},"Institut du Cancer de Montpellier - Val d'Aurelle","Montpellier","France","FR",{"type":19,"coordinates":20},"Point",[21,22],3.87635,43.61093,{"lat":22,"lon":21},{"facility":25,"status":7,"city":26,"state":7,"zip":27,"country":16,"countryCode":17,"cosmosGeoPoint":28,"geoPoint":32,"contacts":7},"Institut Universitaire du Cancer Toulouse - Oncopole","Toulouse","31100",{"type":19,"coordinates":29},[30,31],1.44367,43.60426,{"lat":31,"lon":30},{"facility":34,"status":7,"city":35,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":42,"contacts":7},"Sygros Hospital","Athens","Greece","GR",{"type":19,"coordinates":39},[40,41],23.72784,37.98376,{"lat":41,"lon":40},{"facility":44,"status":7,"city":45,"state":7,"zip":7,"country":36,"countryCode":37,"cosmosGeoPoint":46,"geoPoint":50,"contacts":7},"Aristotle University of Thessaloniki","Thessaloniki",{"type":19,"coordinates":47},[48,49],22.93493,40.64072,{"lat":49,"lon":48},{"facility":52,"status":7,"city":53,"state":7,"zip":7,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":7},"Sant'Orsola-Malpighi Hospital University of Bologna","Bologna","Italy","IT",{"type":19,"coordinates":57},[58,59],11.33875,44.49381,{"lat":59,"lon":58},{"facility":62,"status":7,"city":63,"state":7,"zip":7,"country":54,"countryCode":55,"cosmosGeoPoint":64,"geoPoint":68,"contacts":7},"Clinica Dermatologica dell'Università di Napoli \"Federico II\"","Naples",{"type":19,"coordinates":65},[66,67],14.26811,40.85216,{"lat":67,"lon":66},{"facility":70,"status":7,"city":71,"state":7,"zip":7,"country":54,"countryCode":55,"cosmosGeoPoint":72,"geoPoint":76,"contacts":7},"Fondazione Policlinico A. Gemelli","Roma",{"type":19,"coordinates":73},[74,75],11.10642,44.99364,{"lat":75,"lon":74},{"facility":78,"status":7,"city":79,"state":7,"zip":7,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":7},"Hospital Del Mar","Barcelona","Spain","ES",{"type":19,"coordinates":83},[84,85],2.15899,41.38879,{"lat":85,"lon":84},{"facility":88,"status":7,"city":89,"state":7,"zip":7,"country":80,"countryCode":81,"cosmosGeoPoint":90,"geoPoint":94,"contacts":7},"Hospital General de Fuerteventura","Las Palmas",{"type":19,"coordinates":91},[92,93],-16.16555,28.58232,{"lat":93,"lon":92},{"type":96,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100569149","an-observational-real-world-study-to-evaluate-the-impact-of-dermatological-toxicities-on-the-quality-of-life-in-patients-with-early-breast-cancer-treated-with-adjuvant-endocrine-therapy---bcare-breast-cancer-adjuvant-real-world-evaluation-of-dermatological-adverse-events-100569149",false,"NCT06690489","An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)","Impact of Dermatological Toxicities on Quality of Life in Patients With Early Breast Cancer Exposed to Adjuvant Endocrine Therapy: a Real-world Cross-sectional Study. BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)","BCARE","Inclusion Criteria:\n\n1. Females aged ≥ 18 years at inclusion.\n2. Histologically confirmed diagnosis of EBC, according to the WHO criteria and the TNM classification, at any time before inclusion.\n3. Still being treated with adjuvant endocrine monotherapy, initiated 2 years (up to 1 year and 9 months) to 3 years (up to 3 years and 6 months) before the inclusion in the study.\n4. Signed Informed Consent Form (ICF) or non-opposition, according to local regulations.\n\nExclusion Criteria:\n\n1. Patients not able to read, understand and complete Questionnaires in local language.\n2. with chronic dermatological conditions (treated or not) before initiating the adjuvant endocrine therapy that could interfere with the quality of life.\n3. Patients with concomitant targeted therapies with adjuvant endocrine therapy such as CDK4\u002F6 inhibitors or trastuzumab, and patients with ongoing treatment with neratinib.\n4. Patients having relevant or severe comorbidities requiring complex therapeutic treatment.\n5. Patients having a persistent post-chemotherapy alopecia (at least of grade 1)","FEMALE","18 Years",{"count":108,"type":109},155,"ACTUAL","OBSERVATIONAL","The goal of this European observational study (Frane, Spain, italy, Spain and Greece) is to describe the quality of life related to dermatological toxicities, in adult women patients with Early Breast Cancer (EBC), treated with an ongoing adjuvant endocrine monotherapy initiated for 2 to 3 years ago before inclusion in the study.\n\nIn order to answer these objectives, the patient are completing 4 quality of life questionnaires focussed on dermatological issues (DLQI, Skindex-16, Hairdex and ItchyQoL) at the time of the inclusion.\n\nEarly Breast Cancer (EBC) diagnosis and history, demographics\u002Fclinical characteristics, skin care\u002Fsun protection care and skin toxicities since start of the adjuvant endocrine therapy will be collected by the investigator in the eCRF.",[113,114,115],"Early Breast Cancer","Skin Condition","Quality of Life",[117,118,119,120,121],"Early breast cancer","Adjuvant endocrine therapy","Quality of life","Patient Reported Outcomes","skin toxicities","COMPLETED","2026-01-08",{"date":125,"type":109},"2026-01-12",{"date":127,"type":109},"2024-11-22",{"date":129,"type":109},"2025-11-26",{"name":5,"class":6},9]